Filtered By:
Education: Conferences
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 151 results found since Jan 2013.
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference
Dateline City:
WHITEHOUSE STATION, N.J.
Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the company’s anti-PD-1 immunotherapy; expects to complete application in first half of 2014.
Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant.
Evaluates the role of Merck’s Animal Health and Consumer Care businesses in the company’s strategy for long-term value creation;...
Source: Merck.com - Corporate News - January 13, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
